It's cheap and easy to store, but the Russian vaccine does not yet have approval in Europe.
There are two schools of thought.
Side effects generally indicate a natural immune response and will resolve in a few days.
Our best long-term strategy is to rely on the mRNA vaccines like Pfizer and Moderna.
COVID-19 has shown us that we are not "all in this together" despite what politicians may want us to think.
Due to early logistical planning, Rwanda had the capacity to store 5 million doses before the vaccines arrived.
New study looks at public attitudes to COVID-19 vaccine aid. The results are reassuring.
It's normal for different people to mount stronger or weaker immune responses to a vaccine, but post-shot side effects won't tell you which you are.
The amount of risk from overseas arrivals depends not just on Australia's vaccination rates, but also on the particular circumstances of the country from which people are travelling.
As more people get vaccinated and different facets of society slowly reopen, challenges remain in the nation's quest to get back to normal. Here are five articles that help illuminate the path.
Variants of the original SARS-CoV-2 are now in wide circulation. That means the third wave of COVID-19 has come with new questions about the variants, their effects and what might come next.
After a massive reduction in COVID case numbers and optimism about the vaccine rollout, India has seen a huge second wave of infections.
The fight for vaccine equity needs to stop looking to multilateral institutions for permission and instead focus on the policy tools that are already available to states.
If one adenoviral vaccine is linked with blood clots, it doesn’t mean all vaccines in this family will have that same effect. But it's definitely worth health authorities assessing the data.
The one-dose vaccine developed by Johnson & Johnson is temporarily halted because of potentially serious blood clots seen in six women. An immunologist explains what this means for you.
A vaccine expert breaks down everything you need to know about the Novavax vaccine.
The challenge now is to address the understandable concerns and prevent them from contaminating the broader public dialogue on COVID-19 vaccination.
Analysis of almost 100,000 tweets reveals how news reports can change the way people feel about vaccination.
With changing recommendations about AstraZeneca's COVID-19 vaccine making headlines, many people have questions about its use.
How do we reasonably and accurately balance the risks of the AstraZeneca vaccine against the benefits? Conceptualising risk can be tricky, but the government's latest advice is sensible.